Diabetic Peripheral Neuropathy Clinical Trial
Official title:
Effect Of Ankle Proprioceptive Training On Balance And Risk Of Fall In Patients With Diabetic Peripheral Neuropathy
Verified date | October 2023 |
Source | Riphah International University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Diabetes being a very prevalent condition results in various complications including neuropathy, which can impair various functional outcomes in patients including balance. Ankle proprioceptive training (APT) is an intervention that is used to tackle this problem. The study will compare APT with standard balance training in subjects with diabetic neuropathy.
Status | Completed |
Enrollment | 62 |
Est. completion date | September 30, 2023 |
Est. primary completion date | August 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 60 Years |
Eligibility | Inclusion Criteria: - Known case of diabetic peripheral neuropathy (DPN), - Patients who met the criteria of DN4 scored equal or greater than 4. - Patients who have positive SHARPEND ROMBERG TEST Exclusion Criteria: - Patients with DVT - orthostatic hypotension - Any recent surgery of lower limb - Amputies - Patients with crutches or walking aids - Patients with gangrene - Lower BMI - Acute systemic illness - Vestibular impairment |
Country | Name | City | State |
---|---|---|---|
Pakistan | Capital developmental authority hospital | Islamabad | Islamabad Capital Territory |
Lead Sponsor | Collaborator |
---|---|
Riphah International University |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mini BESTest | Mini BESTest is a 27-item physical performance test that distributes the items among the six sub-systems of static and dynamic balance, including stability limits/verticality, biomechanical constraints, anticipatory postural adjustments, postural responses, sensory orientation and stability in gait. | Baseline | |
Primary | Mini BESTest | Mini BESTest is a 27-item physical performance test that distributes the items among the six sub-systems of static and dynamic balance, including stability limits/verticality, biomechanical constraints, anticipatory postural adjustments, postural responses, sensory orientation and stability in gait. | At 4 weeks | |
Primary | Mini BESTest | Mini BESTest is a 27-item physical performance test that distributes the items among the six sub-systems of static and dynamic balance, including stability limits/verticality, biomechanical constraints, anticipatory postural adjustments, postural responses, sensory orientation and stability in gait. | At 8 weeks | |
Primary | Sharpened Romberg (SR) | The Sharpened Romberg (SR) has been proposed as a quick screening tool for balance. SR requires the client to stand in tandem, with the heel of one foot touching the toe of the other foot, for 30 or 60 seconds. | Baseline | |
Primary | Sharpened Romberg (SR) | The Sharpened Romberg (SR) has been proposed as a quick screening tool for balance. SR requires the client to stand in tandem, with the heel of one foot touching the toe of the other foot, for 30 or 60 seconds. | At 4 weeks | |
Primary | Sharpened Romberg (SR) | The Sharpened Romberg (SR) has been proposed as a quick screening tool for balance. SR requires the client to stand in tandem, with the heel of one foot touching the toe of the other foot, for 30 or 60 seconds. | At 8 weeks | |
Primary | Douleur Neuropathique 4 (DN4) Questionnaire | The Douleur Neuropathique 4 (DN4) Questionnaire is a screening tool for neuropathic pain that includes physical exams and 10 interview questions (DN4-interview). As referred in its original version scores lower than 4 were defined negative and 4 or more as positive. | Baseline | |
Primary | Douleur Neuropathique en 4 (DN4) Questionnaire | The Douleur Neuropathique 4 (DN4) Questionnaire is a screening tool for neuropathic pain that includes physical exams and 10 interview questions (DN4-interview). As referred in its original version scores lower than 4 were defined negative and 4 or more as positive. | At 4 weeks | |
Primary | Douleur Neuropathique en 4 (DN4) Questionnaire | The Douleur Neuropathique 4 (DN4) Questionnaire is a screening tool for neuropathic pain that includes physical exams and 10 interview questions (DN4-interview). As referred in its original version scores lower than 4 were defined negative and 4 or more as positive. | At 8 weeks | |
Primary | Unilateral stance test | Unilateral stance test is used for postural stability. The participant must stand unsupported on one leg. Participants are more likely to fall hurt if they can't maintain the one-leg position for at least five seconds. | Baseline | |
Primary | Unilateral stance test | Unilateral stance test is used for postural stability. The participant must stand unsupported on one leg. Participants are more likely to fall hurt if they can't maintain the one-leg position for at least five seconds. | At 4 weeks | |
Primary | Unilateral stance test | Unilateral stance test is used for postural stability. The participant must stand unsupported on one leg. Participants are more likely to fall hurt if they can't maintain the one-leg position for at least five seconds. | At 8 weeks | |
Primary | The Falls Efficacy Scale International (FES-I) | The Falls Efficacy Scale International (FES-I) measures people's fear about falling. FES-I scores ranging from minimum 7 (no concern about falling) to maximum 28 could be used as a rapid screening tool to evaluate a person's self-reported fear of falling. | Baseline | |
Primary | The Falls Efficacy Scale International (FES-I) | The Falls Efficacy Scale International (FES-I) measures people's fear about falling. FES-I scores ranging from minimum 7 (no concern about falling) to maximum 28 could be used as a rapid screening tool to evaluate a person's self-reported fear of falling. | At 4 weeks | |
Primary | The Falls Efficacy Scale International (FES-I) | The Falls Efficacy Scale International (FES-I) measures people's fear about falling. FES-I scores ranging from minimum 7 (no concern about falling) to maximum 28 could be used as a rapid screening tool to evaluate a person's self-reported fear of falling. | At 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04638556 -
Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
|
||
Completed |
NCT05580705 -
Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy
|
N/A | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT00835757 -
Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT00553592 -
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
|
Phase 2 | |
Recruiting |
NCT05863793 -
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT05041816 -
Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT06074562 -
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Recruiting |
NCT04457531 -
LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy
|
Early Phase 1 | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02056431 -
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01681290 -
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01474772 -
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
|
Phase 3 | |
Completed |
NCT01086150 -
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03447756 -
Titration Study of ABX-1431
|
Phase 1 | |
Completed |
NCT04688671 -
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT04984044 -
Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms
|
N/A | |
Completed |
NCT06130917 -
Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN.
|
N/A | |
Completed |
NCT01496365 -
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 |